Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST) ; volume:12 ; number:1 ; day:12 ; month:5 ; year:2011 ; pages:1-5 ; date:12.2011
Trials ; 12, Heft 1 (12.5.2011), 1-5, 12.2011
- Urheber
-
Tanaka, Shiro
- Beteiligte Personen und Organisationen
-
Sakamori, Yuichi
Niimi, Miyuki
Hazama, Megumi
Kim, Young H.
Yanagihara, Kazuhiro
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-12-120
- URN
-
urn:nbn:de:1111-2016050221359
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tanaka, Shiro
- Sakamori, Yuichi
- Niimi, Miyuki
- Hazama, Megumi
- Kim, Young H.
- Yanagihara, Kazuhiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients
Effect of present versus previous smoking on non-invasive haemodynamics
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients
Effect of present versus previous smoking on non-invasive haemodynamics
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
Erlotinib in pancreatic cancer
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Non-participation in breast cancer screening among previous cancer patients